XBI ETF holdings (NYSE) - Page 2 | MetaTrader

Abrir gráfico completo Full chart

Visão geral Todos os ativos Mapa de calor

Principais ativos Market Value Shares Weight %

ABBV AbbVie Inc 98.3 M 430.4 K 1.3%

GILD Gilead Sciences Inc 98.0 M 798.7 K 1.2%

Avidity Biosciences Inc 98.0 M 1.4 M 1.2%

IONS Ionis Pharmaceuticals Inc 97.5 M 1.2 M 1.2%

Cidara Therapeutics Inc 97.5 M 441.3 K 1.2%

UTHR United Therapeutics Corp 97.4 M 199.9 K 1.2%

Exact Sciences Corp 97.2 M 957.0 K 1.2%

BIIB Biogen Inc 96.0 M 545.8 K 1.2%

MIRM Mirum Pharmaceuticals Inc 96.0 M 1.2 M 1.2%

ALNY Alnylam Pharmaceuticals Inc 95.3 M 239.6 K 1.2%

NTRA Natera Inc 95.2 M 415.7 K 1.2%

CELC Celcuity Inc 94.9 M 951.6 K 1.2%

SRRK Scholar Rock Holding Corp 94.8 M 2.2 M 1.2%

ALKS Alkermes PLC 94.7 M 3.4 M 1.2%

TGTX TG Therapeutics Inc 94.4 M 3.2 M 1.2%

ARWR Arrowhead Pharmaceuticals Inc 93.4 M 1.4 M 1.2%

PTGX Protagonist Therapeutics Inc 92.6 M 1.1 M 1.2%

VKTX Viking Therapeutics Inc 90.8 M 2.6 M 1.2%

INSM Insmed Inc 88.8 M 510.4 K 1.1%

ADMA ADMA Biologics Inc 88.5 M 4.9 M 1.1%

1
2
3
4
5
6
7
8

Notícias

First Quarter Earnings: Sharpening Sector Divergence

Is State Street SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

3 Reasons To Stick With Growth Stocks In Rotating Markets

Seeking Innovation Beyond Tech? Insight On Healthcare Stocks

Biotech Investors Are Tuning Out the MAHA Chaos

Makary's Successor Faces Tough Task Managing FDA Amid Budget Cuts

Maravai LifeSciences: Better Earnings Drive Gains That Ought To Be Sustainable (MRVI)

Preço-alvo da Capricor mantido em US$ 63 pela B.Riley com avanços na FDA

FDA Commissioner Marty Makary Expected To Resign, Ending Turbulent Stint

Why I Now Favor A Barbell Model Over Ray Dalio’s All-Weather Portfolio (SPY)

Juros a descoberto da Intellia lideram alta entre biotechs, diz Baird

Mizuho reduz preço-alvo da Immunocore para US$ 34 após revisão de receita